Compare TASK & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 598.9M | 713.8M |
| IPO Year | 2021 | 2009 |
| Metric | TASK | IRWD |
|---|---|---|
| Price | $7.90 | $4.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $14.70 | $7.67 |
| AVG Volume (30 Days) | 627.1K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 120.00 | ★ 1400.00 |
| EPS | 0.50 | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $5.95 | $57.95 |
| Revenue Next Year | $6.46 | $4.39 |
| P/E Ratio | $16.26 | ★ $7.87 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.47 | $1.05 |
| 52 Week High | $18.39 | $5.78 |
| Indicator | TASK | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 53.43 |
| Support Level | $6.30 | $3.85 |
| Resistance Level | $8.18 | $4.53 |
| Average True Range (ATR) | 0.40 | 0.18 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 77.36 | 66.32 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.